Ocular implant containing a tyrosine kinase inhibitor
The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
1. A sustained release biodegradable ocular implant comprising a hydrogel and a dose of axitinib from about 150 μg to about 1200 μg, wherein the axitinib is dispersed within the hydrogel, and wherein the implant in its dry state prior to implantation is cylindrical; has a length of about 6 mm to about 17 mm and a diameter of 0.2 mm to 0.5 mm; and has a total implant weight of about 0.2 mg to about 1.5 mg.
2. The sustained release biodegradable ocular implant of claim 1 , wherein the implant comprises axitinib in an amount of about 480 μg to about 750 μg.
3. The sustained release biodegradable ocular implant of claim 1 , wherein the implant comprises axitinib in an amount of about 160 μg to about 250 μg.
4. The sustained release biodegradable ocular implant of claim 1 , wherein the implant in its dry state has a total weight of about 0.4 mg to about 1.2 mg.
5. The sustained release biodegradable ocular implant of claim 1 , wherein the implant is cylindrical and in its hydrated state (after 24 hours in phosphate-buffered saline at a pH of 7.2 at 37° C.) has a length of about 6 mm to about 9 mm and a diameter of equal to or less than about 0.8 mm.
6. The sustained release biodegradable ocular implant of claim 1 , wherein the implant is cylindrical and has a ratio of the diameter in the hydrated state to the diameter in the dry state of less than about 5.
7. The sustained release biodegradable ocular implant of claim 1 , wherein the implant is cylindrical and has a ratio of the length in the dry state to the length in the hydrated state of greater than about 0.7.
8. The sustained release biodegradable ocular implant of claim 1 , wherein the implant provides for the release of axitinib at an average rate of about 0.25 μg to about 2.5 μg per day in phosphate-buffered saline at a pH of 7.2 and 37° C. for a period of 30 days under non-sink simulated physiological conditions.
9. The sustained release biodegradable ocular implant of claim 1 , wherein the implant is an intravitreal implant.
10. The sustained release biodegradable ocular implant of claim 1 , wherein the implant provides for the release of axitinib for a period from about 3 months to about 38 months after administration.
11. The sustained release biodegradable ocular implant of claim 1 , wherein the implant provides for the release of axitinib for a period of about 6 to about 9 months after administration.
12. The sustained release biodegradable ocular implant of claim 1 , wherein the hydrogel comprises polyethylene glycol (PEG) units.
13. The sustained release biodegradable ocular implant of claim 12 , wherein the hydrogel comprises PEG units that have a number average molecular weight of about 20,000 Daltons.
14. The sustained release biodegradable ocular implant of claim 12 , wherein the hydrogel comprises crosslinked PEG units and the crosslinks between the PEG units include a group represented by the following formula
wherein m is an integer from 0 to 10.
15. The sustained release biodegradable ocular implant of claim 14 , wherein m is 6.
16. The sustained release biodegradable ocular implant of claim 14 , wherein the PEG units comprise 4-arm and/or 8-arm PEG units.
17. The sustained release biodegradable ocular implant of claim 1 , wherein the axitinib is in the form of particles having a d90 particle size of less than about 30 μm as determined by laser diffraction.
18. The sustained release biodegradable ocular implant of claim 1 , wherein the implant is free or substantially free of antimicrobial preservatives.
19. The sustained release biodegradable ocular implant of claim 1 , wherein the implant in its dry state contains from about 200 μg to about 900 μg axitinib per mm 3 .
20. The sustained release biodegradable ocular implant of claim 1 , wherein the implant in its dry state contains from about 60% to about 75% by weight axitinib and from about 21% to about 31% by weight PEG units (dry composition).
21. The sustained release biodegradable ocular implant of claim 1 , wherein the implant in its dry state contains from about 45% to about 55% by weight axitinib and from about 37% to about 47% by weight PEG units (dry composition).
22. The sustained release biodegradable ocular implant of claim 1 , wherein the implant is an intravitreal implant and comprises from about 540 μg to about 660 μg axitinib, is cylindrical and has in its dry state a length about 6 mm to about 9 mm and a diameter of about 0.3 mm to about 0.4 mm, and in its hydrated state (after 24 hours in phosphate-buffered saline at a pH of 7.2 at 37° C.) has a length of from about 6 mm to about 10.5 mm and a diameter of from about 0.6 mm to about 0.8 mm, and wherein the hydrogel comprises crosslinked 4a20k and 8a20k PEG units, wherein the crosslinks between the PEG units include a group represented by the following formula
wherein m is 6.
23. The sustained release biodegradable ocular implant of claim 1 , wherein the implant is an intravitreal implant and comprises from about 180 μg to about 220 μg axitinib, is cylindrical and has in its dry state a length of about 6 mm to about 9 mm and a diameter of about 0.2 mm to about 0.3 mm, and in its hydrated state (after 24 hours in phosphate-buffered saline at a pH of 7.2, at 37° C.) has a length of from about 6.5 mm to about 8 mm and a diameter of from about 0.7 mm to about 0.8 mm, and wherein the hydrogel comprises crosslinked 4a20k and 8a20k PEG units, wherein the crosslinks between the PEG units include a group represented by the following formula
wherein m is 6.
24. The sustained release biodegradable ocular implant of claim 1 , wherein the implant is loaded in a needle for injection.
25. The sustained release biodegradable ocular implant of claim 24 , wherein the lumen of the needle is occluded by a material that is solid at room temperature and molten at body temperature.
26. A sustained release biodegradable ocular implant comprising a hydrogel and a dose of axitinib from about 150 μg to about 1200 μg, wherein the axitinib is dispersed within the hydrogel, and wherein the implant in its dry state prior to implantation is cylindrical; has a length of about 6 mm to about 17 mm and a diameter of 0.2 mm to 0.5 mm; has a total weight of about 0.2 mg to about 1.5 mg; provides for the release of axitinib at an average rate of about 0.1 μg to about 3 μg per day in phosphate-buffered saline at a pH of 7.2 and 37° C. under non-sink simulated physiological conditions; and in its dry state contains from about 200 μg to about 900 μg axitinib per mm 3 .
27. The sustained release biodegradable ocular implant of claim 26 , that provides for the release of axitinib at an average rate of about 0.1 μg to about 3 μg per day in phosphate-buffered saline at a pH of 7.2 and 37° C. for a period of 30 days under non-sink simulated physiological conditions.